A Study of Pembrolizumab in People With Ultra-Rare Sarcomas

Part of paid clinical trials in Basking Ridge, New Jersey.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT07089992
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Sarcoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pembrolizumab — DRUG
    Q 6 weeks IV infusion Day 1 of each 6-week cycle, up to 8 doses

Study Details

The purpose of the study is to find out if pembrolizumab is a useful treatment that causes few or mild side effects in people with ultra-rare sarcoma. The researchers will also study how the immune system responds to the study treatment. Pembrolizumab is a type of drug called a PD-1 inhibitor. It is designed to block a protein called programmed cell death protein 1 (PD-1) that usually acts as a "brake" on the immune system. Blocking this protein is like releasing the brakes, so that the immune system can target cancer cells and destroy them.

Key Dates

Start date
Dec 4, 2025
Status verified
May 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
32 participants (estimated)
Allocation
NA
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Pleomorphic liposarcoma
    Pembrolizumab Q 6 weeks IV infusion
  • Experimental: PEComa (perivascular epithelial cell tumor)
    Pembrolizumab Q 6 weeks IV infusion
  • Experimental: Epithelioid sarcoma
    Pembrolizumab Q 6 weeks IV infusion
  • Experimental: CIC-rearranged sarcoma
    Pembrolizumab Q 6 weeks IV infusion
  • Experimental: Sclerosing epithelioid fibrosarcoma - low grade fibromyxoid sarcoma
    Pembrolizumab Q 6 weeks IV infusion

Primary Outcome Measure

Response rate [ Time Frame: 12 weeks ]

Central Contacts

Locations (6)

FacilityCityStateZIPSite coordinators
Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)Basking RidgeNew Jersey07920
Robert Maki, MD
[email protected]
646-888-5059
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)MiddletownNew Jersey07748
Robert Maki, MD, PhD
[email protected]
646-888-5059
Memorial Sloan Kettering Bergen (Limited Protocol Activities)MontvaleNew Jersey07645
Robert Maki, MD, PhD
[email protected]
646-888-5059
Memorial Sloan Kettering Cancer Center Suffolk- Commack (Limited Protocol Activities)CommackNew York11725
Robert Maki, MD, PhD
[email protected]
646-888-5059
Memorial Sloan Kettering Cancer Center (All Protocol Activities)New YorkNew York10065
Robert Maki, MD
[email protected]
646-888-5059
Memorial Sloan Kettering Nassau (All Protocol Activities)UniondaleNew York11553
Robert Maki, MD, PhD
[email protected]
646-888-5059

Find similar trials in Basking Ridge, NJ

By research site
Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)· Basking Ridge, NJMemorial Sloan Kettering Monmouth (Limited Protocol Activities)· Middletown, NJMemorial Sloan Kettering Bergen (Limited Protocol Activities)· Montvale, NJMemorial Sloan Kettering Cancer Center Suffolk- Commack (Limited Protocol Activities)· Commack, NYMemorial Sloan Kettering Cancer Center (All Protocol Activities)· New York, NYMemorial Sloan Kettering Nassau (All Protocol Activities)· Uniondale, NY

Related Studies